Announcements Trials
Browse Landscape

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Myeloid 1CNS 1

Conditions

Melanoma 467Skin Neoplasms 145Carcinoma, Basal Cell 94Breast Neoplasms 78Neoplasms 68Lymphoma, T-Cell, Cutaneous 62Lung Neoplasms 57Carcinoma, Squamous Cell 40Carcinoma, Non-Small-Cell Lung 40Mycosis Fungoides 39Uveal Melanoma 38Sezary Syndrome 37Lymphoma, Non-Hodgkin 35Lymphoma 35Keratosis, Actinic 35Pancreatic Neoplasms 34Sarcoma 33Prostatic Neoplasms 33Head and Neck Neoplasms 33Colorectal Neoplasms 33Leukemia, Lymphocytic, Chronic, B-Cell 31Ovarian Neoplasms 30Urinary Bladder Neoplasms 29Multiple Myeloma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, B-Cell, Marginal Zone 28Colonic Neoplasms 28Lymphoma, Mantle-Cell 27Lymphoma, Follicular 27Leukemia 27

Interventions

Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Pruritus × Dermatologic × Clear all
NCT03290989 2017-09-25

PRURITCC

University Hospital, Brest

Completed
100 enrolled
Dermatologic

Pruritus, Skin Neoplasms

NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡